Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047720 · ClinicalTrials.gov registry record · NA
Scheduled Awakenings for the Treatment of Nocturnal Enuresis
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03047720: Completed NA study, sponsored by Indiana University.
NCT03047720 is a NA study that has completed, run by Indiana University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03047720, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a simple effectiveness trial to determine if the Lully Sleep Guardian has any effect on benign nocturnal enuresis.
Primary Outcome
Participants were asked to enter responses daily into a Lully Study app.The questions the participant was prompted to answer: Did your child have a bed wetting episode last night? Answered by yes or no.
Interventions
- DEVICE Lully Sleep Guardian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-11-04 |
| Est. Completion | 2018-08-07 |
| Phase | NA |
What the finished NCT03047720 record still lists
NCT03047720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Lully Sleep Guardian is the first listed.
NCT03047720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03047720 about?
NCT03047720 is a clinical study titled "Scheduled Awakenings for the Treatment of Nocturnal Enuresis". This study is a simple effectiveness trial to determine if the Lully Sleep Guardian has any effect on benign nocturnal enuresis.
What is the current status of trial NCT03047720?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2016-11-04. Estimated completion is 2018-08-07.
What interventions are being tested in trial NCT03047720?
The interventions under investigation include: Lully Sleep Guardian (DEVICE).
Who is sponsoring clinical trial NCT03047720?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03047720's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI